Medincell: mdc-tjk's (teva's codename: tev-44749) phase 1 study pharmacokinetics to be presented for the first time by teva at sirs 2023 (may 11-15, 2023, toronto, canada)

Montpellier, france--(business wire)--an original presentation describing pharmacokinetic characteristics of an investigational long-acting subcutaneous formulation of olanzapine (mdc-tjk or tev-44749) will be communicated by medincell's partner teva pharmaceuticals at the 2023 schizophrenia investigational research society (sirs) later this month. data to be presented comes from a 127-participant phase 1 clinical study evaluating, among other things, the pharmacokinetics of single ascending do.
TEVA Ratings Summary
TEVA Quant Ranking